Vaccine · 2022 · 11 citations · 26 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyImmunization SchedulesPre-exposure ProphylaxisVaccinationVaccine EfficacyVaccine SafetyVaccine-preventable DiseasesCell-based VaccineComparative Vaccine SafetyPre-exposure Prophylaxis EffectivenessPre-exposure Prophylaxis ImplementationRabies Exposure ProphylaxisRabies Pre-exposure ProphylaxisRabies VaccinesRabies Virus
Shorter rabies pre-exposure prophylaxis (PrEP) regimens may offer improved convenience and feasibility over classic 3-week regimens, for example in regions with poor access to vaccines or for travelers to rabies-endemic regions. In this multicenter, open-label, controlled trial, 570 healthy participants aged 2-64 years were randomized to receive: 1-week PrEP (vaccination days [D]0 and 7; Group 1) or classic 3-week PrEP regimen (D0, D7, and D21; Group 2) with one 1.0 mL intramuscular [IM] dose of human diploid cell culture rabies vaccine (HDCV) at each visit; 1-week PrEP with two 0.1 mL intradermal (ID) HDCV doses at each visit (Group 3); or 1-week PrEP with one 0.5 mL IM dose (Group 4) or two 0.1 mL ID doses (Group 5) of Vero cell rabies vaccine (PVRV) at each visit. Participants received simulated post-exposure prophylactic (PEP) vaccination (two IM or ID doses of HDCV or PVRV three days apart) one year later. Rabies virus neutralizing antibody titers and seroconversion (titers ≥ 0.5 IU/mL) rates were assessed 14 days and up to 1 year post-PrEP, and pre- and post-PEP. Safety was assessed throughout the study. Seroconversion rates were high 14 days post-last PrEP injection (ranging from 96.7 % to 97.2 % across groups 1, 3-5; 1-week PrEP) and reached 100 % in Group 2 (3-week PrEP). Non-inferiority of Group 1 versus Group 2 in terms of seroconversion rates 14 days post-last PrEP injection (primary objective) was not demonstrated. After simulated PEP, all groups showed rapid and robust immune responses, with all but one participant achieving seroconversion (titers ≥ 0.5 IU/mL). There were no safety concerns, and the tolerability profiles of the vaccines were similar across the groups. A 1-week, IM or ID PrEP regimen with HDCV or PVRV provided efficacious priming, enabling rapid robust anamnestic responses to simulated PEP 1 year later across age groups. ClinicalTrials.gov number: NCT03700242. WHO Universal Trial Number (UTN): U1111-1183-5743.
26
Estimating the Global Burden of Endemic Canine Rabies
Katie Hampson, Laurent Coudeville, Tiziana Lembo et al. · PLoS neglected tropical diseases · 2015 · 1.8K citations · Full text
Charles E. Rupprecht, Deborah J. Briggs, Catherine Brown et al. · Annals of Emergency Medicine · 2010 · 288 citations · Full text
Agam K. Rao, Deborah J. Briggs, Susan M. Moore et al. · MMWR Morbidity and Mortality Weekly Report · 2022 · 69 citations · Full text
Patrick Soentjens, Petra Andries, Annelies Aerssens et al. · Clinical Infectious Diseases · 2018 · 57 citations · Full text